Bacitracin Andlignocaine
4 brands · 4 companies · product forms
Opportunity snapshot
Who competes here
Top companies by brand count · leader share 25%
Price room
max/min price ratio 28.93x across 11 trusted points (Rs 77.26-2235.5). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.
Why this score
Launch attractiveness
40% supply-gap(12) + 25% price-variation(100) + 20% low-competition(90) + 15% supply-disruption(0), damped by confidence(90). Higher = more attractive, less crowded opportunity.
Market saturation
4 canonical companies and 4 brands compete (saturation pegged at 30 companies / 150 brands).
Price room
max/min price ratio 28.93x across 11 trusted points (Rs 77.26-2235.5). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.
Regulatory risk
No DRAP alerts on this molecule's brands.
Confidence
Reduced by: no ATC code.
Packaged brief for this moderate opportunity?
Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.
See packaged reports All 3868 molecules